Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 75 clinical trials
VP-16 Ifosfamide Dexamethasone L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma (VIDL+ASCT)

Open-labeled, multicenter phase II study of VIDL (VP-16, Ifosfamide, Dexamethasone, L-asparaginase) chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation in

ejection fraction
etoposide
neutrophil count
platelet count
dexamethasone
  • 6 views
  • 26 Jan, 2021
  • 1 location
Sintilimab Pegaspargase and Anlotinib for Stage IV Natural Killer /T-cell Lymphoma

high-dose chemotherapy.

  • 0 views
  • 05 Feb, 2021
  • 1 location
Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias

The purpose of this study is to evaluate the safety and efficiency of personalized targeted therapy in combination with high-dose chemotherapy as part of a preparative regimen before T-depleted

  • 0 views
  • 26 Jan, 2021
  • 1 location
Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy

ineligible for high dose chemotherapy and ASCT

platelet count
high dose chemotherapy
hematologic malignancy
dexamethasone
daratumumab
  • 2 views
  • 27 Jan, 2021
  • 3 locations
Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL.

>Consolidation therapy after induction therapy includes whole-brain radiation therapy, high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (auto-SCT), and high

  • 0 views
  • 26 Jan, 2021
  • 1 location
Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

treatment (refractory) or has come back after a period of improvement (relapsed). Giving natural killer cells after high dose chemotherapy may boost the patient's immune system by helping it see the

fludarabine
filgrastim
refractory acute myeloid leukemia (aml)
cytarabine
human chorionic gonadotropin
  • 29 views
  • 27 Jan, 2021
  • 1 location
Panobinostat Gemcitabine Hydrochloride Busulfan and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma

respond to treatment (refractory) or has returned (relapsed). Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving high-dose chemotherapy, such

melphalan
busulfan
arrhythmia
17p deletion
carbon monoxide
  • 0 views
  • 23 Jan, 2021
  • 1 location
Administration of High Dose Thiotepa and Melphalan With Autologous Hematopoietic Stem Cell Transplant in Children and Adolescents With Solid Tumors

, physicians suggest additional therapy with high dose chemotherapy after a good initial response to standard doses of treatment has been obtained, so as to reduce the chance that the tumor will

solid tumour
melphalan
thiotepa
high dose chemotherapy
solid neoplasm
  • 4 views
  • 07 Nov, 2020
  • 1 location
Autologous Peripheral Blood Stem Cell Transplant for Neurologic Autoimmune Diseases

which might include the brain/spinal cord and/or the peripheral nerves. Giving high-dose chemotherapy, including carmustine, etoposide, cytarabine, melphalan, and antithymocyte globulin, before a

antithymocyte globulin
melphalan
nervous
spinal cord disease
multiple sclerosis
  • 154 views
  • 26 Apr, 2021
  • 3 locations
Oral Supplementation of 2'-Fucosyllactose in Allogeneic Bone Marrow Transplant Recipients

High dose chemotherapy and radiation used as preparative regimens in patients undergoing an allogeneic hematopoietic stem cell transplant (HSCT) disrupts intestinal homeostasis by damaging the

allogeneic hematopoietic stem cell transplant
bone marrow transplant
acute graft-versus-host disease
graft versus host disease
  • 0 views
  • 28 Apr, 2021
  • 1 location